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Abstract 
 
Introduction: The mainstays of brain tumor therapy are surgery, radiotherapy and 
chemotherapy. Cancer immunotherapy is explored as an additional treatment 
modality. However, emerging evidence indicates that also radio- and chemotherapy 
have immunological effects in addition to their cytotoxic and cytostatic activities.  
 
Area covered: We summarize the literature on radio- and chemotherapy-mediated 
immunological effects in primary and secondary brain tumors and outline open 
questions within the field. To this end, a literature search was performed using the 
terms “brain tumor”, “immune system”, “immunogenic cell death”, “vaccination”, 
“checkpoint inhibition”, “radiotherapy”, “chemotherapy” and derivations thereof. 
 
Expert Commentary: Immunological effects of chemo- and radiotherapy in brain 
tumors involve direct immunogenic modulations of tumor cells, changes of the 
microenvironment and functional alterations of innate and adaptive immune cells. 
Each treatment modality can exert various effects that comprise both immune-
stimulatory and immunosuppressive mechanisms. A detailed knowledge of these 
mechanisms is indispensable for an optimal combination of conventional anti-tumor 
treatments and novel immunotherapeutic approaches.  
 
 
Keywords: radiotherapy, chemotherapy, immunogenic cell death, vaccination, 
checkpoint inhibition, brain tumor, glioblastoma 
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1. Introduction 
 
Brain tumors are a heterogeneous group of intracranial neoplasms representing the 
most common cancer entity in children and adolescents as well as the seventh most 
common cancer in adults (1). They are systematically separated in primary brain 
tumors that originate from cells within the brain or surrounding tissue such as 
meningeal cells and the more common secondary brain tumors, which represent 
metastases from extracranial neoplasms. Approximately one third of all primary brain 
tumors are malignant, which is defined by histopathological features such as 
increased cellularity, infiltration into the surrounding brain parenchyma and more 
recently by specific molecular alterations like mutations in the isocitrate 
dehydrogenase 1 (IDH1) gene, the alpha thalassemia/mental retardation syndrome 
X-linked (ATRX) gene or the telomerase reverse transcriptase (TERT) promoter (2) in 
gliomas.  
These biological characteristics have therapeutic implications. The vast majority of 
malignant brain tumors cannot be cured by resection alone. Surgery, however, 
remains a key element within the management of these neoplasms in order to obtain 
tissue samples for an accurate histological diagnosis, the determination of molecular 
markers, as well as the reduction of mass effects which may improve progression-
free and overall survival (3, 4). Most treatment regimens against malignant brain 
tumors comprise radiotherapy (RT) and systemic treatment, either sequentially in 
time or in combination. For example, the standard of care for patients with newly 
diagnosed glioblastoma, the most common malignant primary brain tumor in adults, 
comprises maximal surgical resection followed by temozolomide (TMZ)-based 
radiochemotherapy (5). Other guideline-based chemotherapeutic protocols for 
primary brain tumors involve nitrosourea-based regimens such as the combination of 
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procarbazine, lomustine and vincristine (PCV) (6). Secondary brain tumors are 
predominantly treated with surgery and/or radiotherapy (7). Chemotherapeutic agents 
are also active against brain metastases, but are less well studied in randomized 
trials. Typically, the drugs which act best against the primary tumor are also 
considered the most active compounds against brain metastases. Hence, different 
chemotherapy agents are utilized, depending on the histology of the primary tumor. 
Topoisomerase I (topotecan, irinotecan) and II (etoposide, teniposide) inhibitors as 
well as platinum-based agents (cisplatin, carboplatin) are used for the treatment of 
lung cancer brain metastases (8), alkylating drugs such as dacarbazine, TMZ or 
nitrosoureas are used against melanoma or breast cancer manifestations in the brain 
(9, 10). Of note, there is no specific chemotherapeutic agent for the treatment of brain 
metastases. 
In addition to these conventional antitumor therapies, immunotherapy is an arising 
treatment pillar against cancer and various immunotherapeutic approaches are 
currently being studied against primary and secondary brain tumors (11-13). There is 
increasing evidence that radio- and chemotherapy may also have immunological 
effects that can either stimulate or inhibit anti-tumor immune responses. Thus, the 
combination of conventional treatment modalities with novel immunotherapeutics 
may result in additional or even synergistic anti-tumor activity but can also lead to 
deleterious effects. Because of this crucial interaction, we summarize the current 
knowledge of the immune effects of radio- and chemotherapy against brain tumors. A 
detailed understanding of these mechanisms could help guiding novel strategies to 
successfully combine conventional and immunotherapeutic treatment concepts. 
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2. Chemotherapy  
Alkylating chemotherapy is part of the standard treatment regimen against diffusely 
infiltrating gliomas (14) and also used for therapy of brain metastasis, e.g., from 
melanoma (15). The addition of TMZ to radiotherapy prolongs survival of patients 
suffering from glioblastoma or anaplastic glioma without 1p/19q co-deletion (5, 16) . 
The combination of RT and PCV chemotherapy prolongs survival compared to 
radiotherapy alone in patients with 1p/19q co-deleted anaplastic gliomas and low-
grade tumors (17-19). TMZ is orally administered and better tolerated than PCV. Its 
small size of only 194 daltons and its lipophilic properties enable crossing of the 
blood-brain barrier (20). A retrospective case control study demonstrated superior 
efficacy over the functionally similar dacarbazine (DTIC) in preventing isolated central 
nervous system relapses from metastatic melanoma (21). However, a randomized 
phase III trial comparing TMZ and dacarbazine in systemically metastatic melanoma 
demonstrated non-inferiority and did not meet the planned superiority endpoint (22). 
On a mechanistic level, TMZ methylates guanine in DNA which induces a cycle of 
DNA mismatch repair that leads to single- and double-strand breaks. This DNA 
damage triggers autophagy, senescence and apoptosis (23). Interestingly, TMZ may 
have immune-stimulatory and immune-inhibitory activity beyond its cytostatic and 
cytotoxic effects. In preclinical glioma and melanoma models, TMZ induced the cell 
surface exposure of calreticulin (CRT) and the secretion of high-mobility group-1 
protein (HMGB1), which rendered tumor cells more susceptible to T cell-mediated 
killing and phagocytosis (24, 25). CRT, HMGB1 and several other intracellular 
molecules summarized by Garg at el. (26) can act as danger-associated molecular 
pattern molecules (DAMP) upon cell surface translocation or extracellular release 
that stimulate antigen-presenting dendritic cells (DC) and macrophages. If these 
mechanisms accompany treatment-induced cancer cell death, they can potently 
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prime adaptive anti-tumor immune responses characterized by target specificity and 
immunological memory without the requirement of external adjuvants. This immune-
stimulatory mechanism of anticancer therapy has been known as immunogenic cell 
death (27). This TMZ-mediated immune-stimulatory effect has been additionally 
boosted in combination with gene therapy that promotes the expansion of antigen-
presenting cells. This led to long-term survival in murine glioma and intracranial 
melanoma models (28). 
Such immune-stimulatory effects were also observed in clinical trials. Pretreatment of 
patients within phase I clinical trials with TMZ and RT followed by vaccination with 
DC pulsed with autologous tumor lysate was safe and increased tumor antigen-
specific T cells over the treatment course (29, 30). In a phase II multicenter trial 
assessing a peptide vaccine targeting the mutant variant III of epidermal growth 
factor receptor (EGFRvIII), dose-intensified TMZ enhanced humoral and cellular 
vaccine-induced immune responses despite lymphopenia and enrichment of 
regulatory T cells (Tregs) (31). The authors of this study emphasized the correct 
timing of the vaccine relative to the recovery of lymphocytes after TMZ 
administration, which is a consequence of the hypothetical mechanism underlying 
this enhanced immune response after treatment-related lymphopenia. It must be 
assumed that the peripheral lymphocyte pool is reduced by TMZ, which enables 
thymic-independent antigen-driven T cell proliferation within the context of T cell 
homeostasis. In addition to this concept of preconditioning with chemotherapy before 
tumor-specific immunization, the anti-tumor effect of TMZ was also pronounced in the 
post-vaccination phase in glioblastoma patients treated with autologous peptide-
loaded DC (32). It remains unclear whether this was a result of tumor cell 
sensitization to chemotherapy after vaccination or TMZ-boosted anti-tumor immune 
responses in the post-vaccination phase.  
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TMZ may also promote the efficacy of immune checkpoint inhibitors which boost T 
cell function by counteracting co-inhibitory receptors like cytotoxic T lymphocyte-
associated protein 4 (CTLA-4) or programmed cell death protein 1 (PD-1). The 
current knowledge from preclinical and clinical studies on immune checkpoint 
inhibition against primary brain tumors has been summarized by Preusser et al. (33).  
Brain tumors with high mutational load are particularly responsive to immune 
checkpoint inhibition (34). TMZ can induce a “hypermutation phenotype” with 
alterations of DNA mismatch repair (MMR) genes (35, 36). Hence, it needs to be 
assessed whether brain tumor patients that were treated with TMZ will respond better 
to immune checkpoint inhibition. 
Another mechanism of TMZ that could promote an anti-tumor immune response is 
the depletion of immune cells with inhibitory properties. TMZ depletes monocytes, 
which are recruited to the tumor site by chemoattractants and converted to 
immunosuppressive tumor-associated macrophages and myeloid-suppressor-like 
cells (37, 38). Furthermore, low-dose TMZ depletes CD4+CD25+Foxp3+ Tregs, which 
are potent suppressors of innate and adaptive immune cells (39, 40).  
In contrast to these immune-stimulating effects, TMZ may also dampen immune 
responses. Fadul et al. assessed the effect of radiotherapy and TMZ on peripheral 
blood monocytes and lymphocytes in patients with glioblastoma after four weeks of 
treatment. The authors observed a treatment-related shift towards a suppressive 
immunophenotype characterized by enrichment of Tregs and decreased NK and 
CD8+ T cells (41). Another prospective study with a similar design confirmed this 
treatment-related lymphopenia. However, in this study immunophenotyping revealed 
that predominantly B and CD4+ T cells were affected, without a significant enrichment 
of Tregs and stable proportions of NK and CD8+ T cells (42). Thus, a drop in total 
lymphocyte count following TMZ treatment is a common observation, but 
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consequences on individual immune cell subpopulations and immunocellular 
functions remain to be determined in future studies because of the conflicting data. 
Furthermore, these studies assessed the effect of combined radiochemotherapy 
without separating the effects of either therapy alone. Results of a retrospective study 
suggest an association of treatment-related lymphopenia due to radiochemotherapy 
with reduced overall survival in elderly glioblastoma patients (43).  
The potentially inhibiting effects of alkylating chemotherapy on the immune system 
stimulated research efforts to overcome this problem. One strategy is genetic 
engineering of immune cells to convey chemoprotection. Maier et al. transduced 
CD34+ hematopoietic stem cells with lentiviral vectors to overexpress multidrug-
resistance-protein 1 (MDR1) and O6-methylguanine-DNA methyltransferase (MGMT). 
The transduced cells were resistant to alkylating chemotherapy (44), allowing high-
dose treatment with alkylates. Another strategy is the depletion of immune cells with 
suppressive properties. In the context of brain tumors, this was achieved by 
administration of a monoclonal antibody against the high affinity interleukin-2 (IL-2) 
receptor (IL-2Rα/CD25) that is constitutively expressed on Tregs but also transiently 
on effector T cells. Administration of an anti-CD25 antibody during treatment-related 
lymphopenia improved the ratio of effector T cells to Tregs and enhanced the effect 
of anti-tumor immunotherapy (45, 46). However, the authors of these studies 
emphasize the timing of anti-CD25 application during TMZ-mediated lymphopenia to 
reduce the likelihood of interference with effector T cell responses.  
Other studies suggest that the immunogenic effects of alkylating chemotherapy 
depend on the type of tumor antigen (47). Non-mutated tumor-associated antigens 
are recognized by T cell clones that harbor low affinity T cell receptors due to thymic 
selection processes. These antigens induce a slow proliferative T cell response and 
the effector cells are additionally controlled by Tregs. In contrast, mutated antigens 
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are recognized as “non-self” by high-affinity T cell clones and antigen binding results 
in rapid clonal T cell proliferation that is prone to DNA damage (48). As a 
consequence, TMZ could boost the immune response to non-mutated tumor-
associated antigens through Treg depletion, whereas it potentially inhibits the 
response to neo-antigens. Indeed, this was demonstrated in model-antigen 
expressing murine models of melanoma and glioma, in which TMZ abrogated the 
survival benefit gained with a neo-antigen-based vaccination (49).  
 
The immunological effects of other chemotherapeutic agents that are occasionally 
used in brain tumors are less well studied and observations made in extracranial 
neoplasms cannot be simply transferred to the situation in the CNS. Nitrosourea 
compounds comprise lomustine, which is used alone or in combination with 
procarbazine and vincristine in patients with malignant gliomas as well as carmustine 
and fotemustine. The latter is used in metastatic breast cancer and melanoma. A 
single-arm trial of fotemustine in combination with ipilimumab demonstrated long-
term activity against melanoma brain metastases (50, 51), but the putative 
immunological effects of fotemustine remain elusive. Beside systemic administration, 
nitrosoureas are occasionally applied in form of local chemotherapy with 
biodegradable carmustine wafers (52). This treatment, however, is only used at 
single centers and the immunological effects of this local therapy have not been 
assessed so far. Platinum compounds such as cisplatin, oxaliplatin and carboplatin 
may have immunological effects in extracranial cancers through the induction of 
immunogenic cell death (53) or downregulation of PD-L2 which is a ligand to the 
inhibiting immune cell receptor PD-1 (54). However, these drugs have only limited, if 
any, activity against primary brain tumors (55, 56). Irinotecan that belongs to the 
group of topoisomerase inhibitors facilitated immunosuppression due to accumulation 
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of myeloid-derived suppressor cells (MDSC) in colorectal cancer (57). Further studies 
will be needed to understand these mechanisms in more detail. 
 
3. Radiotherapy 
Radiotherapy is an essential component in many treatment regimens against primary 
and metastatic brain tumors either alone or in combination with chemotherapy (6, 
58). The classical paradigm for the mechanism of action involves DNA lesions 
induced by ionizing radiation leading to DNA single- and double-strand beaks and 
ultimately to cell cycle arrest or cell death. In addition, more recent studies 
demonstrated DNA damage-independent bystander effects on non-irradiated 
neighboring cells or abscopal effects, which describe a distant response in tumor 
lesions outside the irradiation field (59). These effects result from complex 
interactions of irradiated cells with the surrounding microenvironment and the 
immune system.  
Several immune-stimulating mechanisms of radiation have been demonstrated in the 
context of brain tumors. Irradiation induces and promotes the release of danger- 
associated molecular pattern molecules like HMGB1 and heat shock protein 70 
(HSP70) from human glioblastoma cells (24, 60). These molecules boost innate 
immune responses. Furthermore, irradiation may help mounting adaptive immune 
responses via upregulation of MHC class I molecules, which was accompanied by an 
increased number of tumor-infiltrating CD4+ and CD8+ T cells in a murine 
glioblastoma model (61). This effect may enhance the efficacy of tumor-antigen 
specific vaccination as shown in murine models of glioblastoma and melanoma brain 
metastases. Only the combination of focal irradiation and a tumor antigen-specific 
vaccination resulted in strong antitumor immune responses and a significant survival 
benefit (61, 62). Beside this direct modulation of tumor cell immunogenicity, 
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irradiation may also induce changes in the microenvironment. Focal brain irradiation 
induced the expression of chemokine (C-C Motif) ligand 2 (CCL2). In mice, this 
chemokine attracts the influx of macrophages and the tumor tropism of adoptively 
transferred T cells to intracranial lymphoma cells (63, 64). However, in gliomas, 
CCL2 may promote tumor cell invasiveness (65) and recruitment of Treg and MDSC 
(66). Furthermore, the expression levels of CCL2 in glioblastoma samples from The 
Cancer Genome Atlas (TCGA) inversely correlated with overall survival and there are 
efforts aiming at inhibiting the CCL2 chemokine-receptor axis (67).  
In glioma patients, a CD8-dominant T cell infiltrate was observed after a combination 
of gene therapy and radiochemotherapy (68, 69). The study consisted of a single 
combined treatment arm without control cohorts. Hence, no conclusions regarding 
the immunogenic effect of each single treatment modality can be drawn. A combined 
preclinical/phase I study on metastatic melanoma demonstrated a predominant role 
of irradiation for the diversification of the tumor-reactive T cell receptor repertoire 
(70). It remains to be determined whether this is the result of tumor antigen induction 
including mutated neo-antigens following irradiation. The same study demonstrated 
that irradiation leads to an upregulation of PD-L1 in melanoma cells, which may 
hamper anti-tumor immunity. This radiation-mediated immunological tolerance 
mechanism was recently confirmed in liver metastases from colorectal cancer (71). In 
both studies, blockade of the PD-1 pathway restored anti-tumor immune responses 
and improved survival emphasizing the rational for a combination of radiation therapy 
and immune checkpoint inhibition. The combination of local irradiation with immune 
checkpoint inhibition resulted in a significant survival benefit in preclinical glioma 
models compared to either treatment alone (72, 73). Other potentially 
immunosuppressive effects are irradiation-mediated upregulation of TGF-β 
expression (74) as well as an enrichment of Tregs (75). Furthermore, radiation may 
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contribute to treatment-related lymphopenia, which occurs in approximately 25-40% 
of patients with newly diagnosed glioblastoma during treatment (76). Mathematical 
modeling of standard radiation schemes revealed that during a course of focal 
radiation for glioblastoma the entire circulating lymphocyte pool receives a potentially 
lymphotoxic dose (77). However, it has been impossible so far to define the net effect 
of radiation therapy alone on the lymphocyte count in brain tumor patients, because 
most patients receive combined radiochemotherapy or concurrent medication like 
steroids. A rescue strategy consisting of pre-radiation lymphocyte harvesting and 
reinfusion after completion of radiation therapy did not significantly increase the total 
lymphocyte count in glioblastoma patients suggesting that a single lymphocyte 
harvest and reinfusion might not be sufficient to correct treatment related-
lymphopenia (78).  
 
4. Concurrent medication in brain tumor management with potential 
immunological effects 
Steroids are often used in the management of brain tumor patients to control tumor-
associated edema or nausea and vomiting (79). They have potent immune-inhibitory 
effects that must be considered in multimodal treatment concepts. Steroids suppress 
pro-inflammatory cytokines and genes associated with NF-κB signaling resulting in 
reduced B and T cell function (80). Recent reports demonstrate that steroid 
administration is an independent predictor of poor outcome in human glioblastoma 
patients and that steroid treatment could interfere with the efficacy of radio- and 
chemotherapy in murine glioma models as well as human glioblastoma patients (81, 
82). As a consequence, steroids should always be tapered when clinically possible 
not only because of well-known side effects including myopathy, diabetes or 
thrombosis, but also due to the reported immunological effects. 
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Anti-angiogenic therapy could be an alternative to steroids. Bevacizumab, a 
recombinant humanized monoclonal antibody that inhibits vascular endothelial 
growth factor (VEGF) is approved by the US Food and Drug Administration as 
monotherapy treatment for patients with recurrent glioblastoma. VEGF itself has 
immunosuppressive properties. It inhibits DC maturation (83) and suppresses T cell 
function (84). In contrast to steroids, anti-VEGF treatment did not interfere with the 
efficacy of radiotherapy in a murine glioblastoma model (81). In addition, it did not 
reduce the therapeutic activity of a DC-based vaccine in patients with newly 
diagnosed glioblastoma (85) and an EGFRvIII-based peptide vaccination in patients 
with recurrent glioblastoma (86).  
 
5. Expert commentary: authors view on current status of the field 
Surgical resection, radiotherapy and chemotherapy are the cornerstones of most 
treatment regimens against primary and secondary brain tumors. Immunotherapy is a 
novel treatment option that resulted in improved outcome of patients with various 
types of extracranial neoplasms. Research efforts aiming at exploring different 
immunotherapeutic strategies against primary and secondary brain tumors are 
ongoing. There is also emerging evidence that radio- and chemotherapy significantly 
impact anti-tumor immune responses. The underlying mechanisms involve direct 
modulation of tumor cells, changes within the microenvironment and alterations of the 
immune cell compartment. 
Some of these effects and their functional consequences have been characterized in 
detail such as the immune-stimulatory induction of immunogenic cell death by 
different chemotherapeutic agents. In contrast, other effects have only been 
assessed superficially so far like changes in gene or protein expression patterns or 
alterations of immune cell subpopulations. The functional immunological 
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consequences of radio- and chemotherapy and the underlying molecular 
mechanisms that ultimately result in anti-tumor activity have to be explored in more 
detail in preclinical and translational studies to understand the relevance of these 
findings. Furthermore, since susceptibility to chemo- or radiotherapy varies among 
different brain tumor entities, it remains to be clarified if this treatment sensitivity also 
affects the treatment-associated immunological consequences. 
Another topic with increasing importance is immune monitoring at the tumor site. The 
clinical course of brain tumors is routinely monitored with sequential MRI scans and 
tumor treatment with chemo- and/or radiotherapy can be accompanied by 
radiographic effects that mimic tumor progression (87). The pathophysiology and 
molecular basis for this treatment-related effects are poorly understood but they 
seem to result from local tissue reaction with inflammation, edema and alteration of 
vessel permeability (88). A systematic analysis about the contribution of treatment-
related inflammatory mechanisms for this phenomenon has not been done. 
Differentiating “pseudoprogression” from real tumor progression is challenging and 
efforts are ongoing to incorporate immune-related considerations into imaging 
assessments (89).  
Radio- and chemotherapy may not only confer immune-stimulatory effects but also 
result in immune-inhibitory activity such as treatment-related lymphopenia that could 
either promote antigen-driven T cell proliferation or deplete effector T cells. The 
conditions that maximize the immune-stimulating potential shifting the balance to 
promote anti-tumor immunity need to be explored in future studies.  
Other therapeutic strategies that are currently being investigated aim at counteracting 
the immunosuppressive effects of radio- and chemotherapy. The emerging class of 
immune checkpoint inhibitors may be suitable to abrogate the immune-inhibiting 
effects of conventional treatments such as radiation-mediated induction of PD-L1. 
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This emphasizes the importance and advantages of combination therapies which 
need to be explored in carefully designed study concepts. So far, most of the 
observed immunological effects derived from radio- or chemotherapy stem from 
preclinical or clinical phase I and II studies which do not allow for final conclusions.  
 
6. Five-year commentary: speculative viewpoint how the field will evolve in 
5 years 
Traditionally, the anti-tumor effects of radio- and chemotherapy were assessed based 
on their cytotoxic and cytostatic potential. Today, technological advances allow for a 
more detailed exploration of these treatment modalities and their immunological 
effects. High-throughput analyses such as DNA and RNA sequencing as well as 
proteomics allow for the detection of immune-related gene signatures, mRNA and 
protein changes in tumor cells and immune cells as well as their modification by 
radio- and chemotherapy. These approaches might reveal new immune-related 
molecules that are altered by these conventional treatments. Furthermore, 
sophisticated immunophenotyping methods like mass cytometry will allow for high-
dimensional tracking of the entire immune cell compartment and might translate the 
molecular modifications to phenotypic changes (90). In addition, methods of 
computational immunology will evolve and might enable integrative analyses from 
molecular up to organismal levels. 
The identification of immunological effects of conventional treatment modalities 
beyond their well-known mechanistic action and their functional characterization will 
trigger the need for predictive markers that may help to guide treatment decisions.  
Multimodal treatment regimens that combine radio- and chemotherapy with new 
immunotherapeutic strategies will be tested in detail in the upcoming years.  
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7. Key issues:  
• Radiotherapy and chemotherapy are established cornerstones for brain tumor 
therapy and have not only cytostatic and cytotoxic effects, but also various 
immunological effects 
• Mechanistically, these immune-effects comprise direct immunogenic 
modulations of tumor cells such as the induction of immunogenic cell death, 
changes within the microenvironment and alterations of the phenotypic 
immune cell composition  
• The immunological effects of radio- and chemotherapy in brain tumors 
comprise both immune-stimulating and -inhibitory effects 
• Concurrent medication that is frequently used in conjunction with conventional 
tumor treatment regimens may exert profound immunological effects such as 
the immunosuppressive effects of corticosteroids  
• Strategies that counteract immunosuppressive effects of radio- and 
chemotherapy are currently investigated including anti-PD-1 approaches to 
overcome radiation-mediated PD-L1 induction 
• Technological advances like gene sequencing, proteomics, or mass cytometry 
will continuously reveal more immunological effects of conventional therapies  
• Future trials which explore radio- and/or chemotherapy against brain tumors 
should monitor immunological effects and assess multimodal treatment 
regimens with novel immunotherapeutics 
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